BIIB-113 is under clinical development by and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BIIB-113’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BIIB-113 overview
BIIB-113 is under development for the treatment of Alzheimer's disease. It is administered through oral route. The drug candidate acts by targeting O-GlcNAcase.
Biogen overview
is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company鈥檚 marketed products include Avonex (interferon beta-1a), Vumerity (diroximel fumarate), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); Aduhelm (aducanumab-avwa) for alzheimer鈥檚 disease, and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson’s disease, Lupus, Depression, CNS and neuromuscular disorders, Amyotrophic Lateral Sclerosis, and Alzheimer鈥檚 disease. The company sells its products through direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of BIIB-113’s drug-specific PTSR and LoA scores,
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
